-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Delavirdine
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/136817-59-9.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 136817-59-9 |
| Description | Delavirdine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. |
Product Information
| Synonyms | U 90152; U90152; U-90152; BHAP-U 90152 |
| Molecular Weight | 456.56 |
| Molecular Formula | C22H28N6O3S |
| Canonical SMILES | CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C |
| InChI | InChI=1S/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3 |
| InChIKey | WHBIGIKBNXZKFE-UHFFFAOYSA-N |
| Boiling Point | 732°C at 760mmHg |
| Melting Point | 226-228°C |
| Flash Point | 396.5°C |
| Purity | >98% |
| Density | 1.388g/cm3 |
| Solubility | In Vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20 °C. |
| Complexity | 749 |
| Exact Mass | 456.19435995 |
| Index Of Refraction | 1.68 |
| In Vitro | Delavirdine inhibited recombinant HIV-1 RT at a 50% inhibitory concentration (IC50) of 0.26 microM. Delavirdine blocked the replication in peripheral blood lymphocytes of 25 primary HIV-1 isolates. Delavirdine had low cellular cytotoxicity, causing less than 8% reduction in peripheral blood lymphocyte viability at 100 microM. |
| In Vivo | The mean values for the maximum concentration in serum (C(max)) of ritonavir, the area under the concentration-time curve from 0 to 12 h, and the minimum concentration in serum (C(min)) of ritonavir before the addition of delavirdine were 14.8 +/- 6.7 micro M, 94 +/- 36 micro M. h, and 3.6 +/- 2.1 micro M, respectively. These same parameters were increased to 24.6 +/- 13.9 micro M, 154 +/- 83 micro M. h, and 6.52 +/- 4.85 micro M, respectively, after the addition of delavirdine(P is <0.05 for all comparisons). |
| PSA | 118.81000 |
| Target | IC50 Value: 0.26 uM (Recombinant HIV-1 RT) Target: HIV-1 reverse transcriptase; NNRTI |
| Vapor Pressure | 2.74E-21mmHg at 25°C |
| XLogP3-AA | 2.4 |
